Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, ...

HIV and oncology product sales drove growth, with significant gains for Biktarvy and Trodelvy. Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised ...

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of ...

The three key products to look out for are Gilead’s anito-cel, Trodelvy and domvanalimab. JP Morgan sees continues to be bullish about the healthcare company, with a note ahead of its Q3 results ...

Gilead Sciences (NASDAQ:GILD) shares fell -11% premarket on Monday after the biopharma company reported disappointing results from a late-stage trial for Trodelvy (sacituzumab govitecan-hziy).

Trodelvy shows effectiveness in treating metastatic triple-negative breast cancer, supported by real-world data. Common side effects include neutropenia, anemia, and fatigue, but are generally ...

Trodelvy's FDA approval for bladder cancer was rescinded due to unmet survival endpoints in the TROPICS-04 study. The drug remains approved for certain breast cancer treatments, highlighting its ...